Regeneron Pharmaceuticals, Inc. closed at $796.01 on September 25, 2026, a decline of 0.69% from the previous session. The move added to a broader 30-day retreat that has pulled the stock down 4.50% over the past month.
Despite the recent pressure, Regeneron has managed a 0.87% gain over the trailing seven-day period, suggesting some near-term stabilization after the longer-term slide. The stock's market capitalization stood at $82.55 billion at the close.
The session's modest loss kept REGN in negative territory on a monthly basis, with the daily dip outweighing the week's incremental recovery. No single catalyst was identified in the available data to account for the divergence between the short- and medium-term trends.
At $796.01, Regeneron remains a large-cap name in the biopharmaceutical sector, though its 30-day performance reflects sustained selling pressure that the past week's gains have only partially offset.
